Novartis launches single infusion for Paget's disease

Novartis has launched Aclasta, an intravenous formulation of the bisphosphonate zoledronic acid indicated for the treatment of Paget's disease of the bone.

The recommended dose of Aclasta is a single intravenous infusion of 5mg in 100ml aqueous solution administered via a vented infusion line over at least 15 minutes.

Clinical trials have shown that a single 5mg infusion of Aclasta achieves a more sustained biochemical remission, defined as either normalisation of serum alkaline phosphatase or a reduction of at least 75% from baseline in total serum alkaline phosphatase at the end of 6 months, than oral risedronate 30mg daily for 60 days.

Furthermore, prolonged observation of patients who responded to treatment has shown that at a mean of 630 days beyond the six-month initial trial, 98% of patients maintained a therapeutic response versus 50% of those who received risedronate, and the rate of relapse was also significantly lower (2% vs 43%).

Aclasta is presented as a 5mg per 100ml solution at a basic NHS price of £283.74 per 100ml.

Further information: Novartis Pharmaceuticals UK Ltd, Frimley Business Park, Frimley, Camberley, Surrey GU16 7SR. Tel: (01276) 692255.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in